With ops spanning Belgium and China, Full-Life inks $245M buyout to beef up radiopharma pipeline
From the day they incorporated Full-Life Technologies just over a year ago, Lanny Sun and his co-founders knew they wanted to in-license and acquire promising radiopharmaceutical programs that would fit right into the supply chain and logistics network they’re building.
They’ve now found the target. Full-Life has put together a $245 million deal to buy out Focus-X Therapeutics, a tiny startup working out of New Jersey.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.